The PRECIOUS Study: Predicting Crohn’s & Colitis Outcomes in the United States
If you are between the ages of 16-80 and suffer from Crohn’s disease or ulcerative colitis (UC), you may be eligible to participate in this research study.
What is this study about?
The PRECIOUS study is testing the ability of a blood test called PredictSURE IBD™ to determine whether your disease will follow a mild or aggressive course. The test has already been demonstrated to work well in a UK population, so the PRECIOUS study aims to confirm this result in a different group of patients.
Who can participate?
- The target patient population is newly diagnosed, treatment-naive patients with active Crohn’s disease or UC
- Not currently on steroids, and at least 7 days since last steroid use
- Experiencing a flare or period of active disease
- Not scheduled to start biologics as first-line therapy
Involvement in this study does not require any additional visits to your gastroenterologist, primary care physician or any additional treatments that would not otherwise be needed. The study will run for up to 12 months.
The only difference to your medical care is that as part of the study, you will be asked to provide one extra 2.5 ml (approximately half a teaspoon) blood sample at the beginning of the 12-month period.
What are the benefits?
If the study is successful, it will provide further evidence for the use of the test to drive treatment decisions in IBD and will be the first step towards personalized medicine in the US. We will reimburse any reasonable travel and parking costs up to a value of $50.